All In Biotech

Drug Trial Radar · NCT00722371

MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)

A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

Last checked: Nov 19, 2026Latest source record: May 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,615 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,615

Actual

Start

Sep 5, 2008

Primary completion

Oct 26, 2010

Study completion Mar 25, 2011

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 25, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 78 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate the efficacy and safety of sitagliptin and pioglitazone co-administration in comparison with sitagliptin and pioglitazone monotherapy in patients with type 2 diabetes.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • Sitagliptin phosphateDrug

    Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.

  • Pioglitazone hydrochlorideDrug

    Pioglitazone 15 mg, 30 mg, or 45 mg tablets or capsules (blinded) orally once daily for 54 weeks. Participants randomized to receive pioglitazone 45 mg as monotherapy or in combination with sitagliptin were to start on pioglitazone 30 mg at Week 1 and undergo uptitration to pioglitazone 45 mg at Week 4.

  • Matching placebo to sitagliptinDrug

    Matching placebo to sitagliptin orally once daily for 54 weeks.

  • Matching placebo to pioglitazoneDrug

    Matching placebo to pioglitazone tablets or capsules orally once daily for 54 weeks.

  • MetforminDrug

    Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hemoglobin A1C (A1C) at Week 24Time frame: Baseline and Week 24
  2. Change From Baseline in A1C at Week 54Time frame: Baseline and Week 54

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.